Carter P - Search Results

1

Tunable antibodies.

Weiner LM, Carter P. Weiner LM, et al. Among authors: carter p. Nat Biotechnol. 2005 May;23(5):556-7. doi: 10.1038/nbt0505-556. Nat Biotechnol. 2005. PMID: 15877072 No abstract available.

2

The rollercoaster ride to anti-cancer antibodies.

Weiner LM, Carter P. Weiner LM, et al. Among authors: carter p. Nat Biotechnol. 2003 May;21(5):510-1. doi: 10.1038/nbt0503-510. Nat Biotechnol. 2003. PMID: 12721576 No abstract available.

3

An efficient route to human bispecific IgG.

Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. Merchant AM, et al. Among authors: carter p. Nat Biotechnol. 1998 Jul;16(7):677-81. doi: 10.1038/nbt0798-677. Nat Biotechnol. 1998. PMID: 9661204

4

Binders from the deepest vaults.

Carter P. Carter P. Nat Biotechnol. 1996 Mar;14(3):267. doi: 10.1038/nbt0396-267. Nat Biotechnol. 1996. PMID: 9630883 No abstract available.

5

Temporal evolution of the electric field accelerating electrons away from the auroral ionosphere.

Marklund GT, Ivchenko N, Karlsson T, Fazakerley A, Dunlop M, Lindqvist PA, Buchert S, Owen C, Taylor M, Vaivalds A, Carter P, André M, Balogh A. Marklund GT, et al. Among authors: carter p. Nature. 2001 Dec 13;414(6865):724-7. doi: 10.1038/414724a. Nature. 2001. PMID: 11742392

6

More reflection, less written ?

Carter P. Carter P. Educ Prim Care. 2022 Jun 29:1. doi: 10.1080/14739879.2022.2090284. Online ahead of print. Educ Prim Care. 2022. PMID: 35770331 No abstract available.

7

Addressing Residential Segregation as a Social Determinant of Health.

Carter PM, Zimmerman MA. Carter PM, et al. JAMA Netw Open. 2022 Jun 1;5(6):e2222619. doi: 10.1001/jamanetworkopen.2022.22619. JAMA Netw Open. 2022. PMID: 35767263 Free article. No abstract available.

8

Impact of the COVID-19 pandemic on individuals with nystagmus and an exploration of public assumptions about the condition: an electronic questionnaire study.

Rennie K, Alagendran R, Lee H, Griffiths H; Nystagmus U. K. Eye Research Group (NUKE), Self J. Rennie K, et al. BMC Ophthalmol. 2022 Jun 20;22(1):268. doi: 10.1186/s12886-022-02484-x. BMC Ophthalmol. 2022. PMID: 35718783 Free PMC article.

9

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.

Berlak M, Tucker E, Dorel M, Winkler A, McGearey A, Rodriguez-Fos E, da Costa BM, Barker K, Fyle E, Calton E, Eising S, Ober K, Hughes D, Koutroumanidou E, Carter P, Stankunaite R, Proszek P, Jain N, Rosswog C, Dorado-Garcia H, Molenaar JJ, Hubank M, Barone G, Anderson J, Lang P, Deubzer HE, Künkele A, Fischer M, Eggert A, Kloft C, Henssen AG, Boettcher M, Hertwig F, Blüthgen N, Chesler L, Schulte JH. Berlak M, et al. Among authors: carter p. Mol Cancer. 2022 Jun 10;21(1):126. doi: 10.1186/s12943-022-01583-z. Mol Cancer. 2022. PMID: 35689207 Free PMC article.

10

Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8).

Sreekantha RK, Mussari CP, Dodd DS, Pasunoori L, Hegde S, Posy SL, Critton D, Ruepp S, Subramanian M, Salter-Cid LM, Tagore DM, Sarodaya S, Dudhgaonkar S, Poss MA, Schieven GL, Carter PH, Macor JE, Dyckman AJ. Sreekantha RK, et al. Among authors: carter ph. ACS Med Chem Lett. 2022 Apr 25;13(5):812-818. doi: 10.1021/acsmedchemlett.2c00049. eCollection 2022 May 12. ACS Med Chem Lett. 2022. PMID: 35586440

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results